Dr. Reddy's Laboratories announces the launch of Metaxalone Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Metaxalone Tablets, USP 800 mg, a therapeutic equivalent generic version of Skelaxin® (metaxalone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Skelaxin® brand and generic had U.S. sales of approximately $139 million MAT for the most recent twelve months ending in July 2017 according to IMS Health*.

Dr. Reddy's Metaxalone Tablets, USP 800 mg are available in the bottle count size of 100.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2196.8 as compared to the previous close of Rs. 2208.55. The total number of shares traded during the day was 32668 in over 1874 trades.

The stock hit an intraday high of Rs. 2205 and intraday low of 2165.7. The net turnover during the day was Rs. 71608714.

Skelaxin® is a trademark of King Pharmaceuticals Research and Development, Inc.

*IMS National Sales Perspective: Retail and Non-Retail MAT July 2017

Source : Equity Bulls

Keywords